Investor Meetings October 2018

Save this PDF as:

Size: px
Start display at page:

Download "Investor Meetings October 2018"

Transcription

1 Investor Meetings October 2018

2 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this presentation include, among others, statements regarding the potential size of the current and future market opportunities for our various products and product candidates and our various assumptions related thereto, our lung cancer strategy, the design and expected timing of initiation, completion, and data readouts from our various ongoing and planned niraparib, TSR-042, TSR-033, TSR-022, and combination studies, the expected timing of various regulatory filings, and potential indications for our products and product candidates. Forward-looking statements in this presentation involve substantial risks and uncertainties that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks related to competition, the uncertainties inherent in the execution and completion of clinical trials, uncertainties surrounding the timing of availability of data from clinical trials, uncertainties surrounding our ongoing discussions with and potential actions by regulatory authorities, risks related to manufacturing and supply, risks related to intellectual property, uncertainties related to our projected expenses, and other matters that could affect the availability or commercial potential of our products and product candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2017 and Quarterly Report on Form 10-Q for the quarter ended June 30,

3 Building a Leading Oncology Company Robust Oncology Portfolio Led by ZEJULA ZEJULA PARP Inhibitor Approved in U.S. and Europe Development programs ongoing with monotherapy and combinations in gynecologic and lung cancers TSR-042 anti-pd-1 TSR-022 anti-tim-3 TSR-033 anti-lag-3 Registration trial ongoing; BLA on track for 2H 2019 Enables strategic development and commercial flexibility in combination with ZEJULA, TSR-022, TSR-033 TSR-042 combination trial ongoing Anti-PD-1 experienced NSCLC patients TSR-042 combination trial ongoing Multiple tumor types TSR-075 anti-pd-1/lag-3 bispecific IND-enabling studies Multiple tumor types NSCLC: Non-small Cell Lung Cancer 3

4 Development Strategy Focused on Gynecologic and Lung Cancers Gynecologic Cancers: Ovarian, Endometrial Lung Cancer Ovarian Expand current ZEJULA label to treatment setting Move into front line Endometrial No approved drug in 2L endometrial Current agents provide 10-14% ORR Lung cancer Despite the availability of anti-pd-1 therapy, a large number of patients do not respond in the front-line setting anti-pd-1 monotherapy is now standard of care in patients with TPS >50% 2 nd /3 rd line PD-1 experienced market opportunity is growing rapidly ZEJULA (PARP) TSR-042 (PD-1) ZEJULA and TSR-042 Partnerships & Collaborations (Prostate, Bladder, Breast, Pancreatic) TPS: Tumor Proportion Score 4

5 ZEJULA Strategy to Expand PARPi Maintenance Use Aligned with KOLs to Drive Awareness to Providers & Patients Leverage KOL Awareness and Support Engagement of Providers Activation of Patients Collaborations in place with ovarian cancer thought leaders to raise awareness through several new initiatives: Publication of real-world evidence NCCN engagement to better reflect the importance of PARPi maintenance KOL position papers supporting maintenance treatment Launching unbranded peer-to-peer programs to engage community oncologists Engaging with EMR vendors and provider organizations to develop workflow and care plan enhancements that facilitate maintenance therapy decisions Expanded investment in Continuing Medical Education (CME) Launching new PR campaign to inform and educate patients & families Partnering with advocacy groups to encourage dialogue with physicians EU ZEJULA launch experience supports growth opportunity for U.S. PARPi adoption. 5

6 ZEJULA New Indications Would Address Every Stage of a Women s Journey with Ovarian Cancer OVARIAN CANCER PATIENT JOURNEY 1 st Line 2 nd Line 3 rd Line 4 th, 5 th, 6 th Line+ Treatment Maintenance Treatment Recurrent Maintenance Treatment Recurrent Maintenance Treatment Recurrent Maintenance ZEJULA clinical trials FIRST PRIMA OVARIO NOVA NOVA QUADRA NOVA AVANOVA AVANOVA AVANOVA TOPACIO Follow-on Study: Platinum Resistant Ovarian Cancer (ZEJULA +TSR-042) Women who respond to platinum for <6 months are considered platinum-resistant Current ZEJULA indication Fully enrolled / completed trials Enrolling / expected to enroll patients by year-end TSR-042: anti-pd-1 antibody; AVANOVA trial in collaboration with ENGOT 6

7 ZEJULA NOVA Study Primary Endpoint PFS Results 42% of patients estimated without progression or death 24 months following the start of chemotherapy gbrcamut Cohort 27% of patients estimated without progression or death 24 months following the start of chemotherapy Non-gBRCAmut Cohort Progression free Survival (%) Niraparib Placebo Progression free Survival (%) Niraparib Placebo Time Since Randomization (months) Time Since Randomization (months) Treatment Niraparib (N=138) Placebo (N=65) PFS Median (95% CI) (Months) Hazard Ratio (95% CI) p-value 21.0 (12.9, NR) (3.8, 7.2) (0.173, 0.410) p< % of Patients without Progression or Death 12 mo 18 mo 62% 50% 16% 16% Treatment Niraparib (N=234) Placebo (N=116) PFS Median (95% CI) (Months) Hazard Ratio (95% CI) p-value 9.3 (7.2, 11.2) (3.7, 5.5) (0.338, 0.607) p< % of Patients without Progression or Death 12 mo 18 mo 41% 30% 14% 12% Overall Survival (<20% patient deaths) HR 0.73 (95% CI, to 1.125; p=0.1545) PFS was analyzed using a 2-sided log-rank test using randomization stratification factors, and summarized using the Kaplan-Meier 7 methodology; Hazard ratios with 2-sided 95% confidence intervals were estimated using a stratified Cox proportional hazards model, with the stratification factors used in randomization

8 ZEJULA Moving to 1 st Line with PRIMA Ovarian Cancer With High Risk for Progression, Stage 3 or 4 (N=733) CR or PR Following Platinum Based Chemotherapy Enrolled 1 st line patients regardless of BRCA status Stratify on HRD (2:1 randomization) Niraparib 200 mg Daily Treatment 1 Placebo Daily Treatment 200 mg starting dose for most patients based on body weight & platelet count Blinded, pooled interim safety data at ESMO Primary Endpoint Endpoint Assessment Progression-free Survival (PFS) Top-line data expected in late 2019 Secondary Endpoints OS PFS2 Patient reported outcomes Safety & Tolerability Time to CA-125 progression 1 Trial was amended to incorporate a starting dose of 300 mg for patients 77 kg (170 lbs) and platelets 150K/uL, with a 200mg starting dose for all others 8

9 ZEJULA AVANOVA: Niraparib + Bevacizumab Recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer w/high-grade serous/endometrioid histology Phase 1, N = 12 Phase 2, N=94 Stratify on HRD and PFI (>6-12 months or 12+ months) Objectives Phase 1/2 AVANOVA Trial Niraparib + Bevacizumab Niraparib: 300mg Bevacizumab: 15mg/kg Niraparib: 300mg Phase 1: Safety and tolerability of bevacizumabniraparib combination Phase 2: Progression-Free Survival (PFS) in niraparib vs. niraparib + bevacizumab Potentially synergistic activity via simultaneous inhibition of antiangiogenesis and DNA repair Chemotherapy free treatment regimen Goal to improve PFS with bevacizumab or niraparib monotherapy Supported by VEGFi + PARPi exploratory work (Avastin and others) Promising initial combination activity observed in AVANOVA Update of Phase 1 data at ESMO 2017 Disease control rate of 92% 6/12 (50%) ORR, including 1 CR and 5 PRs Median progression-free survival (PFS) was 49 weeks Phase 2 is ongoing 80% power for HR 0.57 (8 vs. 14 months) Phase 2 data in 1H 2019 Initial data presented at ASCO 2016, abstract 5555 AVANOVA is an Investigator Sponsored Trial (IST) SD: Stable disease CRC: Colorectal cancer HR: Hazard ratio GBM: Glioblastoma multiforme 9

10 TSR-042 Registration Strategies Focuses on Endometrial Cancers Accelerated Approval (U.S.) Population Endometrial Cancer 2L/3L Endometrial Cancer (GARNET) Includes MSS (70-75%) and MSI-H (25-30%) endometrial cancer ~7,600 patients treated in U.S ~7,600 patients treated in EU MSI-H Endometrial, MSI-H Colorectal and other MSI-H Tumors (GARNET) 2L/3L MSI-H Endometrial 2 MSI-H Cancers 3L/4L MSI-H Colorectal & Other MSI-H Tumors Phase 3 Randomized 1L Endometrial Cancer MSI-H Endometrial, MSI-H Colorectal and other MSI-H Tumors Full Approval Populations Includes MSS and MSI-H patients ~11,000 patients treated in U.S. ~11,000 patients treated in EU 2L/3L MSI-H Endometrial 2 3L/4L MSI-H Colorectal & Other MSI-H Tumors U.S. Market Opportunity: 1 $500M (2L/3L) to $1.5B (1L) Endometrial Cancer is an Area of High Unmet Need with No FDA Approved Therapies in 2L Endometrial 1 Based on market pricing of FDA approved anti-pd-1 therapies; 2 MSI-H Endometrial accounts for ~50% of MSI-H tumors Kantar Health estimated 2018 epidemiology numbers MSI-H: microsatellite instability-high 10

11 TSR-042 is the Foundation of our Lung Strategy PARP PD-1 TIM-3 Niraparib TSR-042 TSR-022 ZEJULA+ TSR-042 in 1L (JASPER) Data 1H 19 GARNET: 2L NSCLC n=65 Data Q4 18 P2 TSR-042 vs. SOC in 1L NSCLC FPI Q1 19 2/3L TSR TSR-022 in PD-1 experienced (AMBER) Data Q4 18 & 1H 19 Data to Guide Potential Registration Opportunities >450 patients, including >120 lung cancer patients have been treated with TSR

12 NSCLC Treatment Landscape Patients Treated Annually 1 TPS <49% 2/3 of 1L patients TPS 50% ~1/3 of 1L patients PD-1 Monotherapy PD-1 + Chemo First Line 110,000 (US) 135,000 (EU5) Platinum Containing Chemo Regimen PD-1 + Platinum Containing Chemo Regimen PD-1 Monotherapy TPS 50% KEYNOTE 024 (n=305) KEYNOTE 042 (n=1,274) KEYNOTE 189 (n=616) 2nd / 3rd Line 115,000 (US) 110,000 (EU5) PD-1 Monotherapy Platinum Containing Chemo Regimen ORR 45% 39.5% 61.4% mpfs 10.3 months 7.1 months 9.4 months Single-agent Chemo (e.g. docetaxel) PD-1 Experienced Efficacy Benchmarks ORR Single-agent Chemo (docetaxel) 3 ~10% Market research with KOLs and community oncologists support physician preference for PD-1 monotherapy in majority of first-line TPS 50% patients 2 Entinostat (HDACi) + pembrolizumab 4 10% (7/72) Durvalumab + tremelimumab 5 5% (4/78) Sitravatinib (TKI) + nivolumab 6 26% (6/23) mpfs: median PFS; NSCLC: Non-small cell lung cancer; TPS: Tumor Proportion Score 1 Stage IIIb and IV NSCLC excluding ALK/EGFRm patients, Kantar Health estimated 2018 epidemiology numbers; 2 IPSOS Oncology Monitor NSCLC, primary market research studies, external market research; 3 docetaxel PI studies TA317 and TAX320; 4 Hellmann et al.,wclc 2018; 5 Garon et al., ASCO 2018; 6 Mirati corp. presentation, includes unconfirmed responses; KEYNOTE 024, 042: squamous + non-squamous; KEYNOTE 189: non-squamous only 12

13 GARNET Data: 2/3L Lung Results by TPS Status Best Percent Change in Sum of Target Lesion Dimensions from Baseline (AACR 2018) 2L+ NSCLC GARNET TSR-042 TPS 0 TPS 1 49% TPS >50% and NA 50% 30% PD PD Ongoing Treatment Discontinued N 2/7 2/8 3/6 ORR [1,2] (%) 29% 25% 50% Percent Change 10% -10% -30% -50% -70% -90% SD SD PD SD SD SD PD SD 1 Opdivo USPI 2 Keytruda USPI 3 ASCO 2016; Abs # 9015 PD = progressive disease; PR = partial response; SD = stable disease; TPS: Tumor Proportion Score MSI-H EC = microsatellite instability-high endometrial cancer; R2PD = recommended phase 2 dose. SD SD SD SD PR PR PR Reference Data: Previously treated NSCLC ORR 20% (Checkmate - 017, squamous) 1 ORR 19% (Checkmate non-squamous) 1 ORR 18% (KN-010, TPS >1%, 2mg/kg) 2 PR PR PR PR 30% Decrease 2L+ NSCLC Keynote -010 Pembrolizumab TPS 0 TPS 1 49% TPS >50% ORR 3 (%) NA ~9 16% ~23 34% NSCLC irorr of ~29% [2,3] is similar ORR of approved anti-pd-1s; but is largely from a PD-L1 TPS < 50% population, demonstrating response rate not driven by PD-L1 status Data as of February 22, 2018 [1] Excludes patients that were not evaluable for tumor response [2] Includes both confirmed and unconfirmed responses [3] Patients who had at least 1 tumor assessment or did not have any tumor assessment but discontinued treatment NA = TPS status not available 13

14 Mechanisms by Which ZEJULA Could Potentiate an Immune Response DNA Repair Immunologically COLD Tumor PARP Inhibition Niraparib PARP Inhibition PD-1 Blockade TSR-042 Immune System Evasion Immunologically HOT Tumor Limited or no presence of activated anti-tumor immune cells in the tumor and a suppressive TME Presence of activated anti-tumor lymphocytes in the tumor and a supportive TME TME: tumor microenvironment *Brown, BJC

15 ZEJULA Rationale in Lung Cancer Effective in platinum responsive ovarian cancer (OC); lung cancer is a platinum responsive disease Both ovarian and lung cancers have high rates of HRD that infer platinum and PARPi sensitivity 1 Demonstrated activity in preclinical lung cancer models and 2 of 2 NSCLC patients in Phase 1 had tumor regression, even at low dose of niraparib (40mg, 316d; 110mg 175d) 2 Demonstrated positive effect on immune system and combination activity with anti-pd-1 in non-clinical models shows activity TOPACIO data indicative of potential positive clinical benefit from PARP + anti-pd-1 combination Phase 2 JASPER Trial 1L NSCLC Goal: Evaluate Safety and Efficacy of Niraparib + PD-1 PD-L1 TPS 50% Niraparib + anti-pd-1 mab Expression Frequency Low BRCA1/2 a 69% Low ERCC1 b 50% ATM loss c 40% PTEN loss d 20-30% Low MSH2 b 18-38% FA methylation e 14% ERCC1 low NSCLC further sensitized to niraparib 1. Marquard et al, Postel-Vinay Nature Rev Clin Onc 9: ; Postel-Vinay Oncogene , Lee et al Clin Can Res 13:832; 2. Sandhu et al Lancet Onc 2013; a. Clin Cancer Res ; b. Nat Rev Clin Onc 9: , c, oncotarget 2016 Villaruz et al, d, Rehman et al Nat Rev Clin Onc 7: , e, Oncogene 23:

16 JASPER Study: Preliminary Stage 1 Data for Niraparib in Combination with Anti-PD-1 in 1L NSCLC in Patients with TPS 50% Best Percent Change in Sum of Target Lesion from Baseline Objective responses by RECIST criteria following treatment with niraparib + pembrolizumab 16

17 TIM-3 is a Key Immune Checkpoint and a Next Generation Cancer Immunotherapy Target TIM-3 biology has been Implicated in T Cell Exhaustion AND Immune Suppression Mediated by Regulatory T Cells and Myeloid Cells CD4/8+ T Cell Exhaustion Myeloid Cells TIM-3 is expressed on macrophages and can also influence MDSC activity in TME* Dendritic Cells Regulatory T Cells T-cell TIM-3 negatively regulates T cell activation and is a marker of exhausted T cells TIM-3 is expressed on regulatory T cells and promotes survival and suppressive activity TIM-3 is expressed on tumor associated dendritic cells and may negatively regulate DC activation *TME = tumor microenvironment. Adapted from Anderson, A. Cancer Immunology Research

18 NSCLC Post-PD-1 Patient Case TSR anti-pd-1 combination dose escalation 63 year-old female diagnosed with Stage IV NSCLC Prior treatment included 1L chemotherapy, 2L anti-pd-1, 3L Tarceva TSR-022 (1 mg/kg) + anti-pd-1 >>> 72% shrinkage Feb Apr

19 AMBER Study: TSR-022 (anti-tim-3) + TSR-042 (anti-pd-1) in Post-PD-1 NSCLC Patients Part 1 TSR TSR-042 (500 mg) 300 mg 900 mg 100 mg Post-PD-1 NSCLC Data presentation at SITC Part 2 TSR TSR-042 (500 mg) Expansion Cohorts 100 mg 300 mg 900 mg = complete = enrolling *enrolled patients Patients must have progressed following treatment with an anti-pd(l)-1 antibody as assessed by the investigator Patients had median of 5 prior lines of therapy Biomarker Analysis: PD-L1, TIM-3, TMB 19

20 Several Key Milestones & Data Readouts Approaching 2H Gynecologic Lung Gynecologic Lung ESMO Congress: GARNET: MSI-H endometrial data with TSR- 042 PRIMA: blinded pooled interim safety data associated with a 200 milligram starting dose based upon baseline weight and platelet count SITC Annual Meeting: GARNET: TSR-042 data in NSCLC patients AMBER: TSR-022 plus TSR-042 combination initial data in post-pd-1 NSCLC CITRINO: TSR-033 monotherapy data QUADRA snda regulatory decision GARNET: TSR-042 data in MSS Endometrial patients submitted to SGO (Mar) AVANOVA P2 data of niraparib vs niraparib + bevacizumab in 1H 2019 PRIMA top-line data of niraparib in 1L OC in late 2019 BLA submission for TSR- 042 in 2H 2019 OVARIO top-line data of niraparib + bevacizumab in 1L OC in late 2019 Initial Phase 2 JASPER lung data with ZEJULA + TSR-042 in 1H 2019 Initiate Phase 2 registration enabling trial of TSR-042 versus standard of care in first-line NSCLC in early 2019 GARNET: final data for TSR-042 MSI-H and 2L Endometrial and NSCLC AMBER data for TSR TSR-042 CITRINO data TSR TSR-042 TSR-042: anti-pd-1; TSR-022: anti-tim-3; TSR-033: anti-lag-3 SITC: Society for the Immunotherapy of Cancers; BLA: Biologics License Application 20

21 Investor Meetings October 2018

Wells Fargo Healthcare Conference September 6, 2018

Wells Fargo Healthcare Conference September 6, 2018 Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are

More information

Citi s 13 th Annual Biotech Conference September 5, 2018

Citi s 13 th Annual Biotech Conference September 5, 2018 Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they

More information

Investor Call. May 19, Nasdaq: IMGN

Investor Call. May 19, Nasdaq: IMGN Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not

More information

Evercore ISI Conference November 29, 2017

Evercore ISI Conference November 29, 2017 Evercore ISI Conference November 29, 2017 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation

More information

Leerink Immuno-Oncology Roundtable Conference

Leerink Immuno-Oncology Roundtable Conference Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private

More information

Merck ASCO 2015 Investor Briefing

Merck ASCO 2015 Investor Briefing Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation

More information

Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.

Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer. Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation

More information

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018 MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward

More information

33 rd Annual J.P. Morgan Healthcare Conference. January 2015

33 rd Annual J.P. Morgan Healthcare Conference. January 2015 33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.

More information

Accelerating our priorities and building our capabilities in Oncology GSK to acquire TESARO

Accelerating our priorities and building our capabilities in Oncology GSK to acquire TESARO Accelerating our priorities and building our capabilities in Oncology GSK to acquire TESARO 3 December 2018 Cautionary statements This presentation may contain forward-looking statements. Forward-looking

More information

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking

More information

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains

More information

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation

More information

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains

More information

Inhibidores de PARP en cáncer de ovario

Inhibidores de PARP en cáncer de ovario Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera

More information

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015 Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking

More information

ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY

ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune

More information

CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS

CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated

More information

Dawson James Conference

Dawson James Conference Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

National Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.

National Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved. National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.

More information

Analyst/Investor Call

Analyst/Investor Call Analyst/Investor Call November 20 th, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations

More information

Recurrent Ovarian Cancer Phase 1b Results

Recurrent Ovarian Cancer Phase 1b Results Recurrent Ovarian Cancer Phase 1b Results December 5 th, 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine

More information

More cancer patients are being treated with immunotherapy, but

More cancer patients are being treated with immunotherapy, but Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH

More information

Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015

Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are

More information

Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)

Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation

More information

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant

More information

FORWARD II PROGRAM UPDATE

FORWARD II PROGRAM UPDATE FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,

More information

Corporate Presentation

Corporate Presentation Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains

More information

Practical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy

Practical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all

More information

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion

More information

CORPORATE PRESENTATION

CORPORATE PRESENTATION CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

Corporate Presentation October 2018 Nasdaq: ADXS

Corporate Presentation October 2018 Nasdaq: ADXS Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements

More information

Clovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET

Clovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3

More information

July, ArQule, Inc.

July, ArQule, Inc. July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical

More information

Corporate Presentation September Nasdaq: ADXS

Corporate Presentation September Nasdaq: ADXS Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and

More information

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018 VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may

More information

CORPORATE PRESENTATION. March 2017

CORPORATE PRESENTATION. March 2017 CORPORATE PRESENTATION March 2017 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking

More information

Five Prime Therapeutics, Inc. Corporate Overview

Five Prime Therapeutics, Inc. Corporate Overview Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities

More information

Targeting the genetic and immunological drivers of cancer

Targeting the genetic and immunological drivers of cancer NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation April 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements

More information

GSK Oncology R&D Update

GSK Oncology R&D Update GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.

More information

Reimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before

Reimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking

More information

ASCO Investor & Analyst Briefing. June 3, 2017

ASCO Investor & Analyst Briefing. June 3, 2017 ASCO Investor & Analyst Briefing June 3, 2017 Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking

More information

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented

More information

NASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.

NASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved. NASDAQ & TSX: IMV BIO Investor Forum October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations

More information

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018 NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements

More information

AACR 2018 Investor Meeting

AACR 2018 Investor Meeting AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains

More information

Update on PARP inhibitors: opportunities and challenges in cancer therapy

Update on PARP inhibitors: opportunities and challenges in cancer therapy Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains

More information

PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective

PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca

More information

Corporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers

Corporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain

More information

Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019

Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains

More information

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in

More information

ASCO Investor & Analyst Briefing May 30, 2015

ASCO Investor & Analyst Briefing May 30, 2015 ASCO Investor & Analyst Briefing May 30, 2015 1 Lonnie Moulder Co-Founder & CEO 2 Safe Harbor Statement Statements made in this presentation that are not descriptions of historical facts are forwardlooking

More information

Corporate Overview. June 2018 NASDAQ:FPRX

Corporate Overview. June 2018 NASDAQ:FPRX Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

More information

Dr. Josep M. Del Campo Clínica Diagonal. Barcelona

Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Nuevas Oportunidades en Cáncer de Ovario Cancer de Ovario: Es una enfermedad única? Cáncer de Ovario: Tratamiento actual Tratamiento inicial: sin cambios

More information

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016 ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within

More information

LION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology

LION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private

More information

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

ESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE

ESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future

More information

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications

More information

Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO

Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO November 24, 2013 Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO Strong interim survival trend (12.0 vs 7.9

More information

Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University

Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

Anti-IL-33 (ANB020) Program

Anti-IL-33 (ANB020) Program Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain

More information

A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG

A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton

More information

Nordic Society of Gynaecological Oncology

Nordic Society of Gynaecological Oncology Nordic Society of Gynaecological Oncology - from a Nordic interest group to a global leader in clinical trials Line Bjørge 14. mars 2017 I 1 Profile NSGO is a non-political, non-profit society Nordic platform

More information

ArQule Jefferies Global Healthcare Conference June 2015

ArQule Jefferies Global Healthcare Conference June 2015 ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning

More information

ASCO 2018 Investor Meeting

ASCO 2018 Investor Meeting ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for

More information

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking

More information

NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017

NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017 NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by

More information

Merrimack Pharmaceuticals: A Refocused R&D Company January 2017

Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JULY 2018 1 Forward-looking statements disclosure This presentation contains forward-looking

More information

8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks

8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks October 19, 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non- Responder

More information

The OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools

The OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

ARQ 087 Overview. FGFR Inhibitor. March 2017

ARQ 087 Overview. FGFR Inhibitor. March 2017 ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform

More information

Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker

Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction

More information

Building a Leading Oncology Franchise

Building a Leading Oncology Franchise ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking

More information

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy

More information

OncoSec Provides 2018 Business Outlook

OncoSec Provides 2018 Business Outlook January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary

More information

Calithera Biosciences. January 2019

Calithera Biosciences. January 2019 Calithera Biosciences January 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the

More information

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March

More information

Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy

Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West

More information

FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019

FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019 FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance

More information

Spectrum Pharmaceuticals

Spectrum Pharmaceuticals Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future

More information

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017 Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,

More information

Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China

Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not

More information

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014 Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,

More information

Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018

Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018 Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress

More information

Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer

Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer Rubraca is now indicated as maintenance treatment for women with recurrent ovarian cancer who are in a complete

More information